Pfizer Inc. (PFE)

41.59
NYSE : Health Technology
Prev Close 41.47
Day Low/High 41.28 / 41.71
52 Wk Low/High 35.32 / 46.47
Avg Volume 23.28M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 230.23B
EPS 1.90
P/E Ratio 21.83
Div & Yield 1.44 (3.31%)

Latest News

Be Careful With Healthcare Stocks Here

Be Careful With Healthcare Stocks Here

Especially when healthcare CEOs discus political issues with analysts and reporters.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

Pets can bring significant profits to companies that cater to this niche market.

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.

Pfizer's Near-Term Correction Could Be Over

Pfizer's Near-Term Correction Could Be Over

Pfizer may be done with its two-month correction but the uptrend may not resume right away.

Jim Cramer: When Is a Miss Not a Miss?

Jim Cramer: When Is a Miss Not a Miss?

When the stock's inexpensive, hated and devoid of love -- that's when.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Pfizer Downgrade to Neutral at UBS

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Pfizer Downgraded to Neutral at JPMorgan

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Bulls Stampeded by Bears as FAANG Stocks Get Trampled

Bulls Stampeded by Bears as FAANG Stocks Get Trampled

A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Pfizer Gets Mixed Bag of Drug Results

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Let's check our indicators.

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer may have poked the bear.

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.

4 Scenarios That Will Impact the Market: Market Recon

4 Scenarios That Will Impact the Market: Market Recon

And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.

Pfizer Downgraded at BMO